Clinical Trial: Greek Registry - Familial Hypercholesterolaemia

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Observational [Patient Registry]

Official Title: Hellenic Registry for Familial Hypercholesterolemia

Brief Summary: Familial hypercholesterolemia (FH) [heterozygous (heFH) or homozygous FH (hoFH)] is a common genetic disorder, characterized by elevated plasma low density lipoprotein (LDL) cholesterol concentration leading (if untreated) to cholesterol deposits in the corneas, eyelids and extensor tendons, rapidly progressing vascular disease, and aortic valve disease.

Detailed Summary:

In contrast, timely recognition and effective treatment of FH can result in a significant improvement in clinical outcomes. The problem is that that majority of individuals with FH are unaware of their disease, particularly that the disease remains silent for many years. In most countries around the world <5% of individuals with FH are identified .

Until lately the prevalence of heFH was traditionally considered to be ~ 1:500 individuals , although clinical and genetic studies suggest that heFH affects ~ 1:200-250 individuals . Thus, the aim of the Hellenic College of Treatment of Atherosclerosis (HCAT) is to 1). Evaluate the prevalence of FH in Greece (FHG-Registry) and 2). To inform population of FH disease.


Sponsor: Hellenic College of Treatment of Atherosclerosis

Current Primary Outcome: the prevalence of Familiar Hypercholesterolaemia in Greece [ Time Frame: 1 month ]

patients with FH will be screened and include in Registry


Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Hellenic College of Treatment of Atherosclerosis

Dates:
Date Received: May 2, 2017
Date Started: January 10, 2017
Date Completion: January 10, 2019
Last Updated: May 15, 2017
Last Verified: May 2017